ALINT Stock Overview
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
IntegraGen SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.66 |
| 52 Week High | €1.57 |
| 52 Week Low | €0.63 |
| Beta | 0.049 |
| 1 Month Change | -5.07% |
| 3 Month Change | -21.08% |
| 1 Year Change | -51.30% |
| 3 Year Change | -64.01% |
| 5 Year Change | -54.98% |
| Change since IPO | -92.79% |
Recent News & Updates
There's No Escaping IntegraGen SA's (EPA:ALINT) Muted Revenues
Feb 17
Pinning Down IntegraGen SA's (EPA:ALINT) P/E Is Difficult Right Now
Apr 19Shareholder Returns
| ALINT | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -6.4% | -3.9% | -0.03% |
| 1Y | -51.3% | -11.7% | 1.8% |
Return vs Industry: ALINT underperformed the French Biotechs industry which returned -12.1% over the past year.
Return vs Market: ALINT underperformed the French Market which returned 1.7% over the past year.
Price Volatility
| ALINT volatility | |
|---|---|
| ALINT Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALINT's share price has been volatile over the past 3 months.
Volatility Over Time: ALINT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 57 | Bernard Courtieu | integragen.com |
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. Its genomic services include transcriptomics, epigenomics, DNA sequencing, NGS testing for cancer research, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics.
IntegraGen SA Fundamentals Summary
| ALINT fundamental statistics | |
|---|---|
| Market cap | €4.35m |
| Earnings (TTM) | -€123.82k |
| Revenue (TTM) | €12.54m |
0.3x
P/S Ratio-35.1x
P/E RatioIs ALINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALINT income statement (TTM) | |
|---|---|
| Revenue | €12.54m |
| Cost of Revenue | €7.10m |
| Gross Profit | €5.44m |
| Other Expenses | €5.57m |
| Earnings | -€123.82k |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Apr 24, 2024
| Earnings per share (EPS) | -0.019 |
| Gross Margin | 43.41% |
| Net Profit Margin | -0.99% |
| Debt/Equity Ratio | 71.8% |
How did ALINT perform over the long term?
See historical performance and comparison